Latest Press Releases
Balmes Transplantation Raises €700,000 in Seed Funding
Marseille, February 6, 2018 – Balmes Transplantation, an early stage innovative biotech company specializing in the fast development of combinations of repurposed drugs against kidney ischemia-reperfusion injury (IRI), announces today that it raised 700,000 euros in seed funding from the company’s top executives, Patrick Berna (founder and CEO) and Guillaume Demarne (CBDO), and from a group of angel investors.
Read full press release (PDF)
Throughout the year, Balmes Transplantation participates in numerous scientific and investor events around the world. Each of these activities gives us an opportunity to showcase our approach and technology, build relationships with clinicians, surgeons and financial partners, and share and gain invaluable insights.
Below are the upcoming events where Balmes Transplantation will be represented.
|RESI Healthtech Week 2018
September 6, 2018 – Boston, MA
This fall, RESI will expand to include the earliest stage companies from the discovery stage through venture stage: companies seeking grants, seed, angel, series A, and series B funding. LSN invites tech hubs, entrepreneurs, investors, strategic partners, and service providers to the RESI conference.
|CREF 2018 – 38th Annual Cardiothoracic Surgery Symposium
September 6-9, 2018 – San Diego, CA
The international, interdisciplinary Cardiothoracic Surgery Symposium is regarded as one of the best perfusion meetings in the world. It also provides exceptional Category 1 CME and CEU education for the entire CVOR team.
November 5-7, 2018 – Copenhagen, DK
BIO-Europe attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts.